Carl Zeiss Meditec AG Elevator Pitch 2025 | Innovation, and growth strategy

Carl Zeiss Meditec AG Elevator Pitch: Key TakeawaysCarl Zeiss Meditec AG: Market Leadership and Strategic OutlookCorporate OverviewIn this engaging elevator pitch, Sebastian Frericks, Head of Investor Relations at Carl Zeiss Meditec AG, provides a concise yet comprehensive introduction to the company’s equity story, market leadership, and growth potential. As one of the world’s leading medical technology companies, Carl Zeiss Meditec dominates the fields of ophthalmology and microsurgery, combining innovation with a strong market presence that instils confidence in our investors and stakeholders.- Revenue: Carl Zeiss Meditec generates €2 billion in annual revenue.- Ownership: 59% of the company is owned by Carl Zeiss AG, a global optics and imaging powerhouse.- Business Segments: -- Ophthalmology: Dominates with innovative solutions across diagnostics, refractive surgery, cataract surgery, and retinal treatments. -- Microsurgery: Focuses on neurosurgery, spinal surgery, ENT, and plastic/reconstructive surgery, with world-leading visualization systems. -- Recurring Revenue: Approximately 47% of revenue is recurring, driven by consumables, software, and services, offering stability and margin growth.Market Leadership and Growth DriversOphthalmology- Refractive Surgery: ZEISS is a global leader with a 40% market share, offering life-changing solutions like SMILE therapy to treat myopia.- Cataract Surgery: Continues to expand market share with premium intraocular lenses and surgical workflows.- Retinal Surgery: Holds a strong #2 position globally, recently enhanced by the DORC acquisition.Microsurgery- ZEISS maintains a 60% global market share in neurosurgical and spinal visualization, delivering cutting-edge intraoperative diagnostic solutions.Geographic Presence and Opportunities- Asia-Pacific: Represents the largest market, driven by high rates of myopia and ageing populations, particularly in China.- US and Europe: Continue to offer significant growth opportunities through portfolio expansion and product rollouts.- Emerging Markets: Heavy investment in India and Southeast Asia positions ZEISS for long-term growth in high-potential regions.Innovation and R&D- R&D Leadership: ZEISS leads the industry in R&D investment, focusing on digitalization, AI, and connected workflows.- Integrated Workflows: The company’s unique approach to combining devices, software, and consumables into unified workflows sets it apart, enhancing clinical outcomes and customer loyalty.Strategic Outlook for FY 2024/25- Challenging Macro Environment: Despite headwinds in the consumer and equipment markets, ZEISS is poised for moderate revenue growth and gradual margin recovery.- Product Launches: New offerings like the KINEVO 900 S and VISUMAX 800 are expected to drive growth in the second half of FY25.- DORC Integration: The full-year consolidation of the DORC acquisition provides significant opportunities in the retinal surgery market.Addressing the Myopia PandemicZEISS addresses the growing global prevalence of myopia, which is projected to affect 50% of the world’s population by 2050. ▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/===============================T&CThis publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.